MBI and Shionogi to cancel agreement

Article

Ultrasound contrast agent developer Molecular Biosystems of SanDiego announced last week that it has exchanged breach-of-contractnotices with its Japanese licensee, Shionogi & Co. of Osaka.MBI said that the two companies have been unable to agree on

Ultrasound contrast agent developer Molecular Biosystems of San

Diego announced last week that it has exchanged breach-of-contract

notices with its Japanese licensee, Shionogi & Co. of Osaka.

MBI said that the two companies have been unable to agree on terms

for canceling their relationship, which covers distribution of

MBI's Albunex agent in Japan, Taiwan, and South Korea. MBI claims

that Shionogi has not diligently pursued the development and distribution

of Albunex in its territory, while Shionogi claims that MBI supplied

it with batches of Albunex that fail to meet adequate quality

standards. MBI said that it will pursue another licensee for Albunex

in the territory.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.